Coskun YAZGAN

Dear Colleague, We invite you to join the Prostate Cancer Care Disparity Analysis Project (ProGAP) — [NCT06612034] — by completing our brief 6–8 minute survey exploring global disparities in prostate cancer treatment. Your voice is essential to shaping more equitable care…

Dear Colleague, Join the Prostate Cancer Care Disparity Analysis Project (ProGAP) (NCT06612034) by taking our quick 6–8 minute survey on global disparities in prostate cancer treatment. Your input is vital in shaping better care. Thank you! Link👇👇👇 qualtricsxmvcbtqb5rf.qualtrics.com/jfe/form/SV_7a……

"“Kidney cancer is at a pivotal turning point, with new long-term data and novel therapies shaping the future of care.” -EMRE YEKEDÜZ, MD, AND YÜKSEL ÜRÜN, MD" ascopost.com/news/june-2025… via @ascopost @yekeduz_emre

🚨 New publication alert! 💊Enzalutamide before ☢️¹⁷⁷Lu-PSMA-617 improves OS vs. abiraterone in mCRPC. Stronger PSMA expression, better sequencing and survival! @OncJournal @OncoAlert @APCCC_Lugano @coskunyazgann @hatice_bolek @nahit_sendur @drdeniztural @yekeduz_emre…

Congrats to rising star @coskunyazgann and every colleague on this great study tackling a real clinical question for patients with mCRPC. Curiosity, teamwork, and care move science forward. Proud of our team’s work! #Oncology #ProstateCancer @OncJournal @APCCC_Lugano @OncoAlert…

🚨 New study alert! 🧪 In our multicenter study of mCRPC patients, we evaluated the impact of enzalutamide vs. abiraterone acetate in the immediately preceding line before ¹⁷⁷Lu-PSMA-617 therapy. 📊 Striking difference in overall survival: ✨ 12.8 months with prior…

🚨 New Era with biomarker-driven trials in Prostate Cancer Therapy lies ahead! 🧬Molecular stratification is revolutionizing metastatic prostate cancer treatment. From ARPIs to PARP inhibitors (BRCA2/PALB2), ICIs (MMRd), and PSMA-targeted therapies, novel targets like EZH2,…

Happy to share our insights in this invited commentary published in "Kidney Cancer" Huge congrats our rising ⭐️⭐️⭐️ fellow @hatice_bolek from @AnkaraUni ! ⁉️Immunotherapy re-challenge appears to have limited efficacy in kidney cancer. What might be the underlying reasons from…

🚨Just weeks after #ASCO25, the latest highlights in genitourinary cancers are now available. The newly released @ASCOPost provides a quick and concise overview. 👀Take another look, this time from our perspective w/ @DrYukselUrun 👉bit.ly/46lgtHK @ASCO…

"“Significant advancements in prostate cancer emphasized treatment intensification and precision-based strategies for localized and castration-sensitive disease.” -EMRE YEKEDÜZ, MD, AND YÜKSEL ÜRÜN, MD" ascopost.com/news/june-2025… via @ascopost @yekeduz_emre

🚨 Just published in @OncJournal ! 🥁Our new study from "Turkish Oncology Group Kidney Cancer Consortium" database... 🚭 Still smoking? It’s costing lives. ❌In metastatic #KidneyCancer , current smokers on immune checkpoint inhibitors had: 🔻Shorter TTF: 4.1 vs. 10.8 months…

🛑A meta-analysis from the DADSPORT Collaboration: Adding hormone therapy to post-op radiotherapy in nonmetastatic prostate cancer improves: ✅ Metastasis-free survival (HR=0.78) ✅ Prostate cancer–specific survival (HR=0.61) 📉 Overall survival benefit small (HR=0.86), limited…

Meta-analysis of 343 transplant recipients w/ advanced cancer treated w/ immune checkpoint inhibitors: 🟰53% cancer deaths at 3 yrs 🟰1-yr survival: 57% (cutaneous SCC), 48% (melanoma), 27% (other solid cancers) 🟰36% acute rejection, 18% graft loss ✅Steroids + mTOR inhibitors…

🚨 Our new study alert! @ElsevierConnect What is the role of comorbidity burden in response to immunotherapy based combos in patients with metastatic renal cell carcinoma? 🎯Endpoints : Overall surival and time to treatment failure High comorbidity 🟰 Worse Outcomes ❓❗️No…

Huge congrats to our rising stars✨✨✨ @BbaharK and @coskunyazgann on their poster at #ASCO25 @ASCO @OncoAlert @OncLive @DrYukselUrun

Excited to share this collaborative effort as a poster at #ASCO2025 @ASCO 🎯 SARS-CoV-2 mRNA-BNT162b2 vaccination is associated with improved PFS and OS in mCRC patients treated with bevacizumab, suggesting potential synergy between the vaccine and cancer therapy. ✅ Clinicians…

According to phase 2/3 AGITG DYNAMIC-III: Colon cancer & 🧬🩸ctDNA: a warning signal. ctDNA is prognostic—not predictive for chemo escalation. Biology speaks louder than stage. Time to rethink adjuvant strategies. @ASCO @OncoAlert #ASCO25

🥁🥁🥁 Thrilled to share that our latest paper is now OUT 📢🥳 🎉It is a distinct honor to share an article with esteemed scholars whose work has profoundly shaped the #ProstateCancer from the past to the future🔝🔝🔝 🎯Key findings from meta-analysis of 3 pioneer trials…